Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677421 | 0.77 | GBA1 (0.38) | CYP11B2 | |
| SCHEMBL30850720 | 0.77 | PIK3CA (0.42) | CYP11B2 | |
| SCHEMBL30850641 | 0.75 | AXL (0.41) | CYP11B2PIM1PIM3 | |
| SCHEMBL30850562 | 0.74 | CYP11B1 (0.42) | CYP11B2 | |
| SCHEMBL31547968 | 0.73 | MAPK1 (0.41) | ACVR1 | |
| SCHEMBL30850608 | 0.70 | XDH (0.40) | CYP11B2PRMT5WDR77 | |
| SCHEMBL30677345 | 0.70 | QPCT (0.50) | — | |
| SCHEMBL3027716 | 0.70 | QPCT (0.50) | — | |
| SCHEMBL680853 | 0.68 | NPC1 (0.45) | — | |
| SCHEMBL4875480 | 0.68 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ADORA3, ADORA2A, ADORA2B | GPR55 348/4885CYP11B2 746/4885PRMT5 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.